Pharmacological management of spinal cord injury: Current status of drugs designed to augment functional recovery of the injured human spinal cord

Journal of Spinal Disorders

Volumn 9, Issue 5, 1996, Pages 355-366

  Greene, Karl A ^a   Marciano, Frederick F ^a   Sonntag, Volker K H ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Clinical drug implementation; Food and Drug Administration; Neuroprotection and regeneration; Secondary neuronal injury; Spinal cord injury

Indexed keywords

21 AMINOSTEROID; 4 AMINOPYRIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIZOCILPINE; FLUNARIZINE; GANGLIOSIDE GM1; METHYLPREDNISOLONE; NALOXONE; NEUROTROPHIC FACTOR; NIMODIPINE; OPIATE ANTAGONIST; SCAVENGER; TIRILAZAD;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG SCREENING; HUMAN; MAJOR CLINICAL STUDY; NERVE REGENERATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD FUNCTION; SPINAL CORD INJURY; TREATMENT PLANNING;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; FREE RADICAL SCAVENGERS; GLUCOCORTICOIDS; HUMAN EXPERIMENTATION; HUMANS; NEUROPROTECTIVE AGENTS; POTASSIUM CHANNEL BLOCKERS; PROGNOSIS; SPINAL CORD INJURIES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0030459563     PISSN: 08950385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (130)

1. Allen AR: Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column: A preliminary report. JAMA 57:878-880, 1911.
2. Allen AR: Remarks on the histopathological changes in the spinal cord due to impact. An experimental study. J Nerv Mental Dis 4:141-147, 1914.
3. Assenmacher DR, Ducker TB: Experimental traumatic paraplegia: The vascular and pathological changes seen in reversible and irreversible spinal-cord lesions. J Bone Joint Surg [Am] 53:671-680, 1971.
4. Bakshi R, Faden AI: Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis. Brain Res 507:1-5, 1990.
5. Beecher HK: Ethics and clinical research. N Engl J Med 274:1354-1360, 1966.
6. Blight AR: Cellular morphology of chronic spinal cord injury in the cat: Analysis of myelinated axons by line-sampling. Neuroscience 10:521-543, 1983.
7. Blight AR: Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Rex Bull 22:47-52, 1989.
8. Blight AR, Toombs JP, Bauer MS. Widmer WR: The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: A phase I clinical trial. J Neurotrauma 8:103-119, 1991.
9. Bowe CM, Kocsis JD, Targ EF, Waxman SG: Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers. Ann Neurol 22:264-268, 1987.
10. Bracken MB: Treatment of acute spinal cord injury with methylprednisolone: Results of a multicenter, randomized clinical trial. J Neurotrauma 8:S47-S50, 1991.
11. Bracken MB: Pharmacological treatment of acute spinal cord injury: Current status and future projects. J Emerg Med 11:43-48, 1993.
12. Bracken MB, Collins WF, Freeman DF, et al.: Efficacy of methylprednisolone in acute spinal cord injury. JAMA 251: 45-52, 1984.
13. Bracken MB, Shepard MJ, Collins WF, et al.: A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury. Results of the second National Acute Spinal Cord Injury Study. N Engl J Med 322:1405-1411, 1990.
14. Bracken MB, Shepard MJ, Collins WJ, Jr., et al.: Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg 76:23-31, 1992.
15. Braughler JM, Chase RL, Neff GL, et al.: A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells. J Pharmacol Exp Ther 244:423-427, 1988.
16. Braughler JM, Hall ED: Correlation of methylprednisolone levels in cat spinal cord with its effects on (Na+ + K+)-ATPase, lipid peroxidation, and alpha motor neuron function. J Neurosurg 56:838-844, 1982.
17. Braughler JM, Pregenzer JF, Chase RL, Duncan LA, Jacobsen EJ, McCall JM: Novel 21-amino steroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 262: 10438-10440, 1987.
18. Bresnahan JC, King JS, Martin GF, Yashon D: A neuroanatomical analysis of spinal cord injury in the rhesus monkey (Macaca mulatta). J Neurol Sci 28:521-542, 1976.
19. Burger A: Approaches to drug discovery. N Engl J Med 270: 1098-1101, 1964.
20. Caudle RM, Isaac L: A novel interaction between dynorphin (1-13) and an N-methyl-D-aspartate site. Brain Res 443: 329-332, 1988.
21. Ceccarelli B, Aporti F, Finesso M: Effects of brain gangliosides on functional recovery in experimental regeneration and reinnervation. Adv Exp Med Biol 71:275-293, 1976.
22. Choi DW: Ionic dependence of glutamate neurotoxicity. J Neurosci 7:369-379, 1987.
23. Choi DW: Calcium-mediated neurotoxicity: Relationship to specific channel types and role in ischemic damage. Trends Neurosci 11:465-469, 1988.
24. 1 on acute spinal cord injury in rats. J Neurosurg 80:97-111, 1994.
25. 1. Brain Res 376:373-377, 1986.
26. Delahunt CS, Lassen LJ: Thalidomide syndrome in monkeys. Science 146:1300-1305, 1964.
27. De Ley G, Leybaert L: Effect of flunarizine and methylprednisolone on functional recovery after experimental spinal injury. J Neurotrauma 10:25-35, 1993.
28. Demopoulos HB, Flamm ES, Pietronigro DD, Seligman ML: The free-radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol Scand Suppl 492:91-119, 1980.
29. DeVivo MJ, Fine PR, Maetz HM, Stover SL: Prevalence of spinal cord injury: A reestimation employing life table techniques. Arch Neurol 37:707-708, 1980.
30. Di Gregorio F, Ferrari G, Marini P, Siliprandi R, Gorio A: The influence of gangliosides on neurite growth and regeneration. Neuropediatrics 15:93-96, 1984.
31. Donaldson DH, Britt DE, Jones C, Jackson CL, Patterson D: Localization of the gene for the ciliary neurotrophic factor receptor (CNTFR) to human chromosome 9. Genomics 17: 782-784, 1993.
32. Ducker TB, Hamit HF: Experimental treatments of acute spinal cord injury. J Neurosurg 30:693-697, 1969.
33. Ducker TB, Kindt GW, Kempf LG: Pathological findings in acute experimental spinal cord trauma. J Neurosurg 35:700-708, 1971.
34. Ducker TB, Zeidman SM: Spinal cord injury: Role of steroid therapy. Spine 19:2281-2287, 1994.
35. Duh M-S, Shepard MJ, Wilberg JE, Bracken MB: The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment. Neurosurgery 35:240-249, 1994.
36. Faden AI: Recent pharmacological advances in experimental spinal injury: Theoretical and methodological considerations. Trends Neurosci 6:375-378, 1983.
37. Faden AI, Jacobs TP: Dynorphin induces partially reversible paraplegia in the rat. Eur J Pharmacol 91:321-324, 1983.
38. Faden AI, Jacobs TP: Opiate antagonist WIN44, 441-3 stereo-specifically improves neurologic recovery after ischemic spinal injury. Neurology 35:1311-1315, 1985.
39. Faden AI, Jacobs TP, Holaday JW: A possible pathophysiological role for endorphins in spinal injury. Fed Proc 39:762, 1980.
40. Faden AI, Jacobs TP, Holaday JW: Opiate antagonist improves neurologic recovery after spinal injury. Science 211:493-494, 1981.
41. Faden AI, Jacobs TP, Zivin JA: Comparison of naloxone and a delta-selective antagonist in experimental spinal stroke. Life Sci 33:707-710, 1983.
42. Faden AI, Molineaux CJ, Rosenberger JG, Jacobs TP, Cox BM: Endogenous opioid immunoreactivity in rat spinal cord following traumatic injury. Ann Neurol 17:386-390, 1985.
43. Federal Drug Administration: Federal Food, Drug, Cosmetic Act. As amended. Code of Federal Regulations, Title 21. 667340:1963 [Abstract].
44. Federal Drug Administration: New Drug Regulations under the Federal Food, Drug, and Cosmetic Act. U. S. Department of Health, Education, and Welfare. 691934:1963 [Abstract].
45. Federal Drug Administration: New Drug Regulations under the Federal Food, Drug, and Cosmetic Act. U. S. Department of Health, Education, and Welfare; Food and Drug Administration. 12066:1972 [Abstract].
46. Feeney DM: Pharmacological modulation of recovery after brain injury: A reconsideration of diaschisis. J Neurol Rehab 5:113-128, 1991.
47. Fehlings MG, Tator CH, Linden RD: The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injury. J Neurosurg 71:403-416, 1989.
48. Feinstein AR: Clinical biostatistics. III. The architecture of clinical research. Clin Pharmacol Ther 11:432-441, 1970.
49. Feinstein AR: Clinical biostatistics. IV. The architecture of clinical research (continued). Clin Pharmacol Ther 11:595-610, 1970.
50. Feinstein AR: Clinical biostatistics - I. A new name - and some other changes of the guard. Clin Pharmacol Ther 11: 135-148, 1970.
51. Feinstein AR: Clinical biostatistics. II. Statistics versus science in the design of experiments. Clin Pharmacol Ther 11:282-292, 1970.
52. Feinstein AR: Clinical biostatistics. V. The architecture of clinical research (concluded). Clin Pharmacol Ther 11:755-771, 1970.
53. Finney DJ: The design and logic of a monitor of drug use. J Chron Dis 18:77-98, 1965.
54. Flamm ES, Young W, Collins WF, Piepmeier J, Clifton GL, Fischer B: A phase I trial of naloxone treatment in acute spinal cord injury. J Neurosurg 63:390-397, 1985.
55. Flamm ES, Young W, Demopoulos HB, DeCrescito V, Tomasula JJ: Experimental spinal cord injury: Treatment with naloxone. Neurosurgery 10:227-231, 1982.
56. Galandiuk S, Raque G, Appel S, Polk HJ Jr: The two-edged sword of large-dose steroids for spinal cord trauma. Ann Surg 218:419-425, 1993.
57. 1 ganglioside. N Engl J Med 324: 1829-1838, 1991.
58. Goldberger ME, Bregman BS, Vierck CJ Jr, Brown M: Criteria for assessing recovery of function after spinal cord injury: Behavioral methods. Exp Neurol 108:113-117, 1990.
59. Goldstein A, Aronow L, Kalman SM: Principles of Drug Action: The Basis of Pharmacology, 2nd ed, ed by A Goldstein, L Aronow, SM Kaiman, New York, John Wiley & Sons, 1974, pp 718-780.
60. Goodkin R, Campbell JB: Sequential pathologic changes in spinal cord injury: A preliminary report. Surg Forum 20:430-432, 1969.
61. 1 effects on chemical, traumatic and peripheral nerve induce lesions to the spinal cord. In: Development and Plasticity of the Mammalian Spinal Cord, ed by ME Goldberger, A Gorio, M Murray, Padua, Italy: Liviana Press, 1986, pp 227-242.
62. Gouarderes C, Attali B, Audigier Y, Cros J: Opiate binding sites in the lumbo-sacral spinal cord from various species. In: Advances in Endogenous and Exogenous Opioids. Proceedings of the International Narcotic Research Conference, ed by H Takagi, EJ Simon, Kyoto, Japan: Kodansha Ltd, 1981, pp 18-20.
63. Greene KA, Marciano FF, Sonntag VKH: Pharmacological strategies in the treatment of spinal cord injuries: A critical review. Crit Rev Neurosurg 4:254-264, 1994.
64. Hall ED: Effects of the 21-aminosteroid U74006F on posttraumatic spinal cord ischemia in cats. J Neurosurg 68:462-465, 1988.
65. Hall ED, Braughler JM: Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med 6:303-313, 1989.
66. Hall ED, Braughler JM, McCall JM: New pharmacological treatment of acute spinal cord trauma. J Neurotrauma 5:81-89, 1988.
67. Hall ED, McCall JM, Chase RL, Yonkers PA, Braughler JM: A nonglucocorticoid steroid analog of methylprednisolone duplicates its high-dose pharmacology in models of central nervous system trauma and neuronal membrane damage. J Pharmacol Exp Ther 242:137-142, 1987.
68. Hall ED, Yonkers PA, Andrus PK, Cox JW, Anderson DK: Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma 9:S425-S442, 1992.
69. Hall ED, Yonkers PA, Horan KL, Braughler JM: Correlation between attenuation of posttraumatic spinal cord ischemia and preservation of tissue vitamin E by the 21-aminosteroid U74006F: Evidence for an in vivo antioxidant mechanism. J Neurotrauma 6:169-176, 1989.
70. Hansebout RR, Blight AR, Fawcett S, Reddy K: 4-Aminopyridine in chronic spinal cord injury: A controlled, double-blind, crossover study in eight patients. J Neurotrauma 10:1-18, 1993.
71. Hayes KC: Investigational trials in progress: 4-aminopyridine for spinal cord injuries. Neurosci Forum 3:1-6, 1993.
72. Hayes KC, Blight AR, Potter PJ, et al.: Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 31:216-224, 1993.
73. Hefti F: Neurotrophic factor therapy for nervous system degenerative disease. J Neurobiol 25:1418-1435, 1994.
74. Hitchon PW, Lobosky JM, Wilkinson TT, Dyste GN, Girton RA III: Impact and balloon compression models of the spinal cord. J Am Paraplegia Soc 11:35-40, 1988.
75. Honigfeld G: Non-specific factors in treatment. I. Review of placebo reactions and placebo reactors. Dis Nerv Sys 25:145-156, 1964.
76. Irwin S: Drug screening and evaluative procedures. Science 136:123-128, 1962.
77. Kakulas BA: Pathology of spinal injuries. Cent Nerv Syst Trauma 1:117-129, 1984.
78. 1Dβ receptors. Circulation 90:1141-1153, 1994.
79. Kraus JF, Franti CE, Riggins RS, Richards D, Borhani NO: Incidence of traumatic spinal cord lesions. J Chronic Dis 28:471-492, 1975.
80. Krumins SA, Faden AI: Traumatic injury alters opiate receptor binding in rat spinal cord. Ann Neurol 19:498-501, 1986.
81. Lenz W: Kindliche missbildungen nach medikament-einnahme während der gravidität? Dtsch Med Wochenschr 86:2555, 1961.
82. Lenz W: Epidemiology of congenital malformations. Ann N Y Acad Sci 123:228-236, 1965.
83. Lindsay RM: Neurotrophic growth factors and neurodegenerative diseases: Therapeutic potential of the neurotrophins and cilary neurotrophic factor. Neurobiol Aging 15:249-251, 1994.
84. Liu D, McAdoo DJ: Methylprednisolone reduces excitatory amino acid release following experimental spinal cord injury. Brain Res 609:293-297, 1993.
85. Marciano FF, Greene KA, Apostolides PJ, Dickman CA, Sonntag VKH: Pharmacologic management of spinal cord injury: Review of the literature. BNI Q 11:2-11, 1995.
86. Marciano FF, Greene KA, Stachowiak MK: Review of neuronal specificity: Why do neurons make connections? BNI Q 8:27-34, 1992.
87. Marzullo G, Hine B: Opiate receptor function may be modulated through an oxidation-reduction mechanism. Science 208:1171-1173, 1980.
88. McBride WG: The teratogenic action of drugs. Med J Aust 2:689-693, 1963.
89. McCurdy PR: Chloramphenicol bone marrow toxicity. JAMA 176:588-593, 1961.
90. Mellin GW, Katzenstein M: The saga of thalidomide: Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 267:1184-1192, 1962.
91. Modell W: Seminar on the clinical evaluation of drugs: The protean control of clinical pharmacology. Clin Pharmacol Ther 4:371-392, 1963.
92. Nemecek S: Morphological evidence of microcirculatory disturbances in experimental spinal cord trauma. Adv Neurol 20:395-405, 1978.
93. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH: Transmural myocardial infarction with sumatriptan. Lancet 341: 861-862, 1993.
94. Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BHC: Postmarketing study of cardiovascular adverse reactions associated with sumatriptan. BMJ 307:1185, 1993.
95. Pearce JM: Sumatriptan in migraine [Editorial]. BMJ 303:1491, 1991.
96. Pointillart V, Gense D, Gross C, et al.: Effects of nimodipine on posttraumatic spinal cord ischemia in baboons. J Neurotrauma 10:201-213, 1993.
97. Prentice ED, Antonson DL, Leibrock LG, Prabhu VC, Kelso TK, Sears TD: An update on the PEG-SOD study involving incompetent subjects: FDA permits an exception to informed consent requirements. IPB: Rev Hum Subjects Res 16:16-18, 1994.
98. Roisen FJ, Bartfeld H, Nagele R, Yorke G. Ganglioside stimulation of axonal sprouting in vitro. Science 214:577-578, 1981.
99. Rosenberg-Schaffer LJ, Lucas JH: An in vitro study of the effects of methylprednisolone on lesioned and uninjured mammalian spinal neurons. Brain Res 605:327-331, 1993.
100. Rosner MJ: National acute spinal cord injury study of methylprednisolone or naloxone [Letter]. Neurosurgery 28:628-629, 1991.
101. Rosner MJ: Methylprednisolone for spinal cord injury. J Neurosurg 77:324-325, 1992.
102. Ross IB, Tator CH: Further studies of nimodipine in experimental spinal cord injury in the rat. J Neurotrauma 8:229-238, 1991.
103. Rümke L: Seminar on the clinical evaluation of drugs. Clinical applications of sequential analysis: An introductory review. Clin Pharmacol Ther 4:531-547, 1963.
104. 1 gangliosides. Neurosci Lett 77:360-366, 1987.
105. Sabel BA, Dunbar GL, Pass B, Stein DG: Gangliosides, neuroplasticity, behavioral recovery after brain damage. In: Brain Plasticity Learning, and Memory, ed by BE Will, P Schmitt, JC Dalrymple-Alford, New York, Plenum Press, 1985, pp 481-493.
106. Sabel BA, Schneider GE: Enhanced sprouting of retinotectal fibers after early superior colliculus lesions in hamsters treated with gangliosides. Exp Brain Res 71:365-376, 1988.
107. Shapiro SA: Methylprednisolone for spinal cord injury [Letter, Comments]. J Neurosurg 77:324-327, 1992.
108. Sharp AA: Chloraphenicol-induced blood dyscrasias: Analysis of 40 cases. BMJ 1:735-736, 1963.
109. Stover SL, Fine PR: The epidemiology and economics of spinal cord injury. Paraplegia 25:225-228, 1987.
110. Stricker BH: Coronary vasospasm and sumatriptan [Letter]. BMJ 305:118, 1992.
111. Tansey MJ, Pilgrim AJ, Martin PM: Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol 33: 310-315, 1993.
112. Taussig HB: A study of the German outbreak of phocomelia: The thalidomide syndrome. JAMA 180:1106-1114, 1962.
113. Thesleff S: Aminopyridines and synaptic transmission. Neuroscience 5:1413-1419, 1980.
114. 1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system. Brain Res 261: 163-166, 1983.
115. Traynor JR, Kelley PD, Ranee MJ: Multiple opiate binding sites in rat spinal cord. Life Sci 31:1377-1380, 1982.
116. Vane JR: A plan for evaluating potential drugs. In: Evaluation of Drug Activities: Pharmacometrics, ed by DR Laurence, AL Bacharach, London, Academic Press, 1964:23-45.
117. Wallace MC, Tator CH, Lewis AJ: Chronic regenerative changes in the spinal cord after cord compression injury in rats. Surg Neurol 27:209-219, 1987.
118. Watson BD, Ginsberg MD: Ischemic injury in the brain: Role of oxygen radical-mediated processes. Ann N Y Acad Sci 559:269-281, 1989.
119. Waxman SG: Aminopyridines and the treatment of spinal cord injury. J Neurotrauma 10:19-24, 1993.
120. Williams RT: Teratogenic effects of thalidomide and related substances. Lancet 1:723-724, 1963.
121. Wilson GM: Seminar on the clinical evaluation of drugs: Difficulties and opportunities in clinical pharmacology. Clin Pharmacol Ther 4:255-260, 1963.
122. Wolf S: The pharmacology of placebos. Pharmacol Rev 11:689-704, 1959.
123. Wolman B: Fatal aplastic anemia. BMJ 2:426-427, 1952.
124. World Medical Association: Declaration of Helsinki: Recommendations guiding doctors in clinical research. World Med J 11:281, 1964.
125. Yoshida S, Abe K, Busto R, Watson BD, Kogure K, Ginsberg MD: Influence of transient ischemia on lipid-soluble antioxidants, free fatty acids and energy metabolites in rat brain. Brain Res 245:307-316, 1982.
126. Young W: The role of calcium in spinal cord injury. Cent Nerv Syst Trauma 2:109-114, 1985.
127. Young W, Flamm ES, Demopoulos HB, Tomasula JJ, DeCrescito V: Effect of naloxone on posttraumatic ischemia in experimental spinal contusion. J Neurosurg 55:209-219, 1981.
128. Young W, Yen V, Blight A: Extracellular calcium ionic activity in experimental spinal cord contusion. Brain Res 253: 105-113, 1982.
129. Zbinden G: The problem of the toxicologic examination of drugs in animals and their safety in man. Clin Pharmacol Ther 5:537-545, 1964.
130. Zubrod CG: Part I. General problems in the selection of drugs for clinical trial. Clin Pharmacol Ther 3:239-241, 1962.